Ignite Creation Date:
2025-12-24 @ 1:56 PM
Ignite Modification Date:
2026-01-25 @ 7:02 AM
Study NCT ID:
NCT01948895
Status:
COMPLETED
Last Update Posted:
2014-11-07
First Post:
2013-09-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Desvenlafaxine Monotherapy in Dysthymia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019263', 'term': 'Dysthymic Disorder'}, {'id': 'D001008', 'term': 'Anxiety Disorders'}, {'id': 'D000098647', 'term': 'Generalized Anxiety Disorder'}, {'id': 'D000072861', 'term': 'Phobia, Social'}, {'id': 'D013313', 'term': 'Stress Disorders, Post-Traumatic'}], 'ancestors': [{'id': 'D003866', 'term': 'Depressive Disorder'}, {'id': 'D019964', 'term': 'Mood Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D010698', 'term': 'Phobic Disorders'}, {'id': 'D040921', 'term': 'Stress Disorders, Traumatic'}, {'id': 'D000068099', 'term': 'Trauma and Stressor Related Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069468', 'term': 'Desvenlafaxine Succinate'}], 'ancestors': [{'id': 'D003511', 'term': 'Cyclohexanols'}, {'id': 'D000441', 'term': 'Hexanols'}, {'id': 'D005233', 'term': 'Fatty Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D003510', 'term': 'Cyclohexanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D008055', 'term': 'Lipids'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 30}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-11', 'completionDateStruct': {'date': '2014-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-11-06', 'studyFirstSubmitDate': '2013-09-19', 'studyFirstSubmitQcDate': '2013-09-19', 'lastUpdatePostDateStruct': {'date': '2014-11-07', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-09-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Montgomery-Åsberg Depression Rating Scale', 'timeFrame': '8 Weeks'}], 'secondaryOutcomes': [{'measure': 'Clinical Global Impression Scale', 'timeFrame': '8 Weeks'}, {'measure': 'Health and Work Performance Questionnaire', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Perceived Stress Scale', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Quality of Life Enjoyment and Satisfaction Scale Quality of Life Enjoyment and Satisfaction Scale Quality of Life Enjoyment and Satisfaction Questionnaire', 'timeFrame': 'Baseline, Week 4, Week 8'}, {'measure': 'Quick Inventory of Depressive Symptomatology', 'timeFrame': 'Baseline, Week 4, Week 8'}, {'measure': 'Survey of Coping Profiles Endorsed', 'timeFrame': 'Baseline, Week 4, Week 8'}, {'measure': 'Sheehan Disability Scale', 'timeFrame': 'Baseline, Week 4, Week 8'}, {'measure': 'Work Productivity and Activity Impairment Questionnaire', 'timeFrame': 'Baseline, Week 8'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Desvenlafaxine', 'Open-label', 'Flexible-dose', 'Dysthymic disorder', 'Anxiety disorders', 'Generalized anxiety disorder', 'Social anxiety disorder', 'Post-traumatic stress disorder'], 'conditions': ['Dysthymic Disorder']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.camh.ca/en/research/Pages/research.aspx', 'label': 'Information about research at the Centre for Addiction and Mental Health'}]}, 'descriptionModule': {'briefSummary': 'This multi-centred study will be conducted at two centres. The design will be an open label, flexible-dose study. This investigation will evaluate the efficacy of Desvenlafaxine monotherapy for patients who meet diagnostic criteria for dysthymia.', 'detailedDescription': 'Primary objective: To investigate the efficacy, safety, and tolerability of open-label desvenlafaxine monotherapy in dysthymic subjects.\n\nSecondary objectives: To evaluate the efficacy of desvenlafaxine on clinical measures relating to improvement of depressive symptoms, quality of life and occupational functioning.\n\nIt is hypothesized that Dysthymic subjects will show significant improvement in depressive symptoms after 8 weeks of treatment with desvenlafaxine. There will be significant improvement in measures of quality of life and stress coping at end of treatment, compared to Baseline. There will also be significant improvement in measures of occupational functioning at end of treatment, compared to Baseline.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male and female patients between 18-65 years.\n* Primary diagnosis of Dysthymic Disorder, as defined by DSM-IV criteria (300.4).\n* MADRS score ≥15 at Screening and Baseline.\n* Supportive therapy, and use of zopiclone for sleep and low-dose benzodiazepines on an as needed basis for anxiety, is allowed at any time.\n* Written informed consent\n\nExclusion Criteria:\n\n* Co-morbid diagnosis of any other Axis I disorders (other than anxiety disorders such as Generalized Anxiety Disorder, Social Anxiety Disorder and Post-traumatic Stress Disorder, provided that Dysthymic Disorder is currently the diagnosis).\n* Meet DSM-IV criteria for a current episode of major depression within two months prior to screening or who have received treatment for a major depressive episode within six months prior to screening.\n* Substance abuse or dependence including alcohol, within 6 months prior to screening.\n* Patients on the following prohibited treatments:\n\n 1. Psychotropics such as other SSRIs, other SNRIs, lithium, sibutramine, tramadol, St. John's Wort, within 2 weeks of randomization\n 2. Agents that impact significantly on serotonin metabolism (e.g. MAOIs, tryptophan, triptans) within 2 weeks of randomization\n* Have received physical therapies for depression (e.g. ECT, rTMS) within the 3 months prior to randomization.\n* Previous non-response to a therapeutic trial of desvenlafaxine (at least 50 mg/day for 2 months).\n* Clinically significant abnormalities in hematology, clinical chemistry, urinalysis or ECG at the screening visit, as judged by the Principal Investigator.\n* Presence of medical or psychiatric condition deemed by the Investigator to interfere with study procedures or endpoint data."}, 'identificationModule': {'nctId': 'NCT01948895', 'briefTitle': 'Desvenlafaxine Monotherapy in Dysthymia', 'organization': {'class': 'OTHER', 'fullName': 'Centre for Addiction and Mental Health'}, 'officialTitle': 'An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia', 'orgStudyIdInfo': {'id': '124/2012'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Single-arm study', 'description': 'Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day', 'interventionNames': ['Drug: Desvenlafaxine']}], 'interventions': [{'name': 'Desvenlafaxine', 'type': 'DRUG', 'otherNames': ['Pristiq'], 'description': "Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.", 'armGroupLabels': ['Single-arm study']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'L5M 4N4', 'city': 'Mississauga', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Medical Research Associates', 'geoPoint': {'lat': 43.5789, 'lon': -79.6583}}, {'zip': 'M5T 1R8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Centre for Addiction and Mental Health', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}], 'overallOfficials': [{'name': 'Arun Ravindran, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Centre for Addiction and Mental Health'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Centre for Addiction and Mental Health', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Arun Ravindran', 'investigatorAffiliation': 'Centre for Addiction and Mental Health'}}}}